Phase II
Safety and efficacy evaluation will be performed on 36 patients from 3 hospitals located in US and Australia
KidneyX seeks breakthrough solutions to transform kidney care
Frontage Clinical Services Inc. announced the implementation of ClinSpark®, a web-based eSource platform, that supports activities from subject recruitment through database lock.
SNF472 significantly reduced progression of cardiovascular calcification in patients with end stage kidney disease (ESKD) receiving hemodialysis
Jonathan Cotliar, chief medical officer of Science 37, a leader in virtual clinical trials, took time to speak with BioSpace about virtual and hybrid clinical trials, the CNS Summit and Science 37.
In its announcement, Solid Biosciences said a patient in its second cohort who was dosed in October experienced a serious adverse event that was deemed related to the drug.
The drug failed to meet the primary endpoints of progression-free survival and overall response rate.
It was a busy week for clinical trial updates for the first week of November. Here’s a look.
Martinsried/ Munich Medigene AG announces that immune monitoring data during the first year of treatment from the ongoing Phase I / II clinical trial with Medigene’s DC vaccine for the treatment of acute myeloid leukemia will be presented at the upcoming ASH Annual Meeting taking place 7 - 10 December 2019 in Orlando, Florida, USA.
uniQure N.V. announced the publication of 26-week interim data from the ongoing Phase IIb clinical trial of etranacogene dezaparvovec, an investigational gene therapy for hemophilia B, in the journal, Blood Advances.
PRESS RELEASES